Streamlining success: How integrated evidence planning transforms asset development
Integrated evidence planning is crucial for aligning evidence generation with stakeholder needs. Explore our robust and actionable insights, with a multistakeholder perspective on optimizing product development and reducing time to market, through strategic evidence generation.
Inside, you'll learn:
- How Integrated Evidence Plans (IEPs) create a path to market approval, access, and uptake
- Practices for IEP implementation and delivery, streamlining and accelerating development
- Strategies to maximize IEP value, including real-world evidence use
- Industry insights on current IEP practices and challenges
Related Insights
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Video
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Related Insights
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Video
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024